drug

dabogratinib

2 stories · latest Sep 14, 2026

Timeline

Tyra Biosciences prices $400 million stock offering

Sep 14FinancingTyra Biosciences, Inc

Tyra reports Q2 2026 results, sets September readout for dabogratinib bladder cancer trial

Aug 4Quarterly updatedabogratinib Tyra Biosciences, Inc